Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
258 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Atherosclerosis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Atherosclerosis - Pipeline Review, H2 2015', provides an overview of the Atherosclerosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Atherosclerosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Atherosclerosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atherosclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Atherosclerosis Overview 10 Therapeutics Development 11 Pipeline Products for Atherosclerosis - Overview 11 Pipeline Products for Atherosclerosis - Comparative Analysis 12 Atherosclerosis - Therapeutics under Development by Companies 13 Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 16 Atherosclerosis - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Atherosclerosis - Products under Development by Companies 21 Atherosclerosis - Products under Investigation by Universities/Institutes 24 Atherosclerosis - Companies Involved in Therapeutics Development 26 Ache Laboratorios Farmaceuticos S/A 26 advanceCor GmbH 27 AFFiRiS AG 28 Arisaph Pharmaceuticals, Inc. 29 Artery Therapeutics, Inc. 30 AstraZeneca Plc 31 Athera Biotechnologies AB 32 AtheroNova Inc. 33 Bayer AG 34 Campus Technologies Freiburg GmbH 35 Cardax Pharmaceuticals, Inc. 36 Cerenis Therapeutics Holding SA 37 ChemoCentryx, Inc. 38 CohBar, Inc. 39 Daiichi Sankyo Company, Limited 40 DoNatur GmbH 41 Dybly AG 42 Exicure, Inc. 43 F. Hoffmann-La Roche Ltd. 44 GenKyoTex S.A. 45 Gilead Sciences, Inc. 46 Jenrin Discovery, Inc. 47 Johnson & Johnson 48 KineMed, Inc. 49 Kowa Company, Ltd. 50 La Jolla Pharmaceutical Company 51 Lead Discovery Center GmbH 52 Merck & Co., Inc. 53 MI.TO. Technology S.r.L. 54 Omeros Corporation 55 OPKO Health, Inc. 56 Otsuka Holdings Co., Ltd. 57 Provid Pharmaceuticals, Inc. 58 Resverlogix Corp. 59 The Medicines Company 60 Therapix Biosciences Ltd 61 Tolerys SA 62 Vascular Biogenics Ltd. 63 Vericel Corporation 64 Virocan Therapeutics Private Limited 65 Vitae Pharmaceuticals, Inc. 66 Atherosclerosis - Therapeutics Assessment 67 Assessment by Monotherapy Products 67 Assessment by Combination Products 68 Assessment by Target 69 Assessment by Mechanism of Action 73 Assessment by Route of Administration 76 Assessment by Molecule Type 78 Drug Profiles 80 6860766 - Drug Profile 80 AEM-28 - Drug Profile 81 AG-01 - Drug Profile 82 AHRO-001 - Drug Profile 83 AHRO-002 - Drug Profile 85 AHRO-003 - Drug Profile 86 AM-0010 - Drug Profile 87 AmVidcm-009 - Drug Profile 88 anacetrapib - Drug Profile 89 Annexin A-5 - Drug Profile 91 apabetalone - Drug Profile 93 ARI-1778 - Drug Profile 96 Artpep-2 - Drug Profile 97 ATH-03 - Drug Profile 98 ATH-04 - Drug Profile 99 ATH-05 - Drug Profile 100 ATH-06 - Drug Profile 101 AZ-876 - Drug Profile 102 BAY-606583 - Drug Profile 103 BSN-272 - Drug Profile 104 CCX-771 - Drug Profile 105 CDX-085 - Drug Profile 106 Cell Therapy for Atherosclerosis - Drug Profile 108 Cellular Immunotherapy for Atherosclerosis - Drug Profile 109 CER-209 - Drug Profile 110 CM-7 - Drug Profile 111 COR-2 - Drug Profile 112 D-4F - Drug Profile 113 DIAS-2 - Drug Profile 114 Drug for Atherosclerosis - Drug Profile 115 Drugs to Activate TLR3 for Atherosclerosis - Drug Profile 116 Drugs to Antagonize NMDA Receptor for Atherosclerosis - Drug Profile 117 DYB-186 - Drug Profile 118 EP-80317 - Drug Profile 119 FX-5A - Drug Profile 120 Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile 121 Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile 122 Gene Therapy to Target miR-145 for Atherosclerosis - Drug Profile 123 GKT-831 - Drug Profile 124 GYY-4137 - Drug Profile 125 Humanin - Drug Profile 127 INV-88 - Drug Profile 129 ISIS-APOARx - Drug Profile 130 ITP-01 - Drug Profile 131 ixmyelocel-T - Drug Profile 132 JD-2000 Series - Drug Profile 135 JD-5000 Series - Drug Profile 136 JD-6000 Series - Drug Profile 137 K-312 - Drug Profile 138 K-877 - Drug Profile 139 KM-011 - Drug Profile 141 KRP-206 - Drug Profile 142 leucine + niacin - Drug Profile 143 LJPC-6417 - Drug Profile 144 LPC-01 - Drug Profile 145 MCS-18 - Drug Profile 146 MDCO-216 - Drug Profile 148 melittin - Drug Profile 150 Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile 151 Monoclonal Antibody to Inhibit Endothelial Lipase for Atherosclerosis - Drug Profile 153 Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 154 Oligonucleotides to Agonize SRB1 for Atherosclerosis and Lymphoma - Drug Profile 155 P-16 - Drug Profile 157 PC-mAb - Drug Profile 158 Peptides to Inhibit Calcineurin for Rheumatoid Arthritis and Atherosclerosis - Drug Profile 160 PR-15 - Drug Profile 161 Protein for Cardiovascular Diseases - Drug Profile 163 Px-102 - Drug Profile 164 Recombinant Protein for Atherosclerosis - Drug Profile 166 Recombinant Protein for Atherosclerosis and Hepatic Steatosis - Drug Profile 167 Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile 169 RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - Drug Profile 170 RO-6836191 - Drug Profile 171 rPAI-123 - Drug Profile 172 Small Molecule for Atherosclerosis - Drug Profile 173 Small Molecule for Atherosclerosis - Drug Profile 174 Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile 175 Small Molecule to Agonize Liver X Receptor for Atherosclerosis - Drug Profile 176 Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile 177 Small Molecule to Target GPR132 for Atherosclerosis - Drug Profile 178 Small Molecule to Target GPR176 for Atherosclerosis - Drug Profile 179 Small Molecules for Atherosclerosis - Drug Profile 180 Small Molecules for Inflammatory Diseases - Drug Profile 181 Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 182 Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity - Drug Profile 184 Small Molecules to Inhibit Chymase for Atherosclerosis - Drug Profile 185 Small Molecules to Inhibit Lipase for Atherosclerosis - Drug Profile 186 SPX-7233801 - Drug Profile 187 SR-9009 - Drug Profile 188 Stem Cell Therapy for Atherosclerosis - Drug Profile 189 Synthetic Peptide to Inhibit F11R for Atherosclerosis - Drug Profile 190 Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 192 Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile 194 Synthetic Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation - Drug Profile 195 Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 196 Vaccine for Atherosclerosis - Drug Profile 198 Vaccine for Atherosclerosis - Drug Profile 199 Vaccine for Atherosclerosis - Drug Profile 200 VB-201 - Drug Profile 201 VTP-4 - Drug Profile 203 Atherosclerosis - Recent Pipeline Updates 204 Atherosclerosis - Dormant Projects 231 Atherosclerosis - Discontinued Products 236 Atherosclerosis - Product Development Milestones 238 Featured News & Press Releases 238 Appendix 250 Methodology 250 Coverage 250 Secondary Research 250 Primary Research 250 Expert Panel Validation 250 Contact Us 250 Disclaimer 251
List of Tables
Number of Products under Development for Atherosclerosis, H2 2015 18 Number of Products under Development for Atherosclerosis - Comparative Analysis, H2 2015 19 Number of Products under Development by Companies, H2 2015 21 Number of Products under Development by Companies, H2 2015 (Contd..1) 22 Number of Products under Investigation by Universities/Institutes, H2 2015 24 Comparative Analysis by Late Stage Development, H2 2015 25 Comparative Analysis by Clinical Stage Development, H2 2015 26 Comparative Analysis by Early Stage Development, H2 2015 27 Products under Development by Companies, H2 2015 28 Products under Development by Companies, H2 2015 (Contd..1) 29 Products under Development by Companies, H2 2015 (Contd..2) 30 Products under Investigation by Universities/Institutes, H2 2015 31 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 32 Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015 33 Atherosclerosis - Pipeline by advanceCor GmbH, H2 2015 34 Atherosclerosis - Pipeline by AFFiRiS AG, H2 2015 35 Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015 36 Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H2 2015 37 Atherosclerosis - Pipeline by AstraZeneca Plc, H2 2015 38 Atherosclerosis - Pipeline by Athera Biotechnologies AB, H2 2015 39 Atherosclerosis - Pipeline by AtheroNova Inc., H2 2015 40 Atherosclerosis - Pipeline by Bayer AG, H2 2015 41 Atherosclerosis - Pipeline by Campus Technologies Freiburg GmbH, H2 2015 42 Atherosclerosis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015 43 Atherosclerosis - Pipeline by Cerenis Therapeutics Holding SA, H2 2015 44 Atherosclerosis - Pipeline by ChemoCentryx, Inc., H2 2015 45 Atherosclerosis - Pipeline by CohBar, Inc., H2 2015 46 Atherosclerosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 47 Atherosclerosis - Pipeline by DoNatur GmbH, H2 2015 48 Atherosclerosis - Pipeline by Dybly AG, H2 2015 49 Atherosclerosis - Pipeline by Exicure, Inc., H2 2015 50 Atherosclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 51 Atherosclerosis - Pipeline by GenKyoTex S.A., H2 2015 52 Atherosclerosis - Pipeline by Gilead Sciences, Inc., H2 2015 53 Atherosclerosis - Pipeline by Jenrin Discovery, Inc., H2 2015 54 Atherosclerosis - Pipeline by Johnson & Johnson, H2 2015 55 Atherosclerosis - Pipeline by KineMed, Inc., H2 2015 56 Atherosclerosis - Pipeline by Kowa Company, Ltd., H2 2015 57 Atherosclerosis - Pipeline by La Jolla Pharmaceutical Company, H2 2015 58 Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H2 2015 59 Atherosclerosis - Pipeline by Merck & Co., Inc., H2 2015 60 Atherosclerosis - Pipeline by MI.TO. Technology S.r.L., H2 2015 61 Atherosclerosis - Pipeline by Omeros Corporation, H2 2015 62 Atherosclerosis - Pipeline by OPKO Health, Inc., H2 2015 63 Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 64 Atherosclerosis - Pipeline by Provid Pharmaceuticals, Inc., H2 2015 65 Atherosclerosis - Pipeline by Resverlogix Corp., H2 2015 66 Atherosclerosis - Pipeline by The Medicines Company, H2 2015 67 Atherosclerosis - Pipeline by Therapix Biosciences Ltd, H2 2015 68 Atherosclerosis - Pipeline by Tolerys SA, H2 2015 69 Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H2 2015 70 Atherosclerosis - Pipeline by Vericel Corporation, H2 2015 71 Atherosclerosis - Pipeline by Virocan Therapeutics Private Limited, H2 2015 72 Atherosclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2015 73 Assessment by Monotherapy Products, H2 2015 74 Assessment by Combination Products, H2 2015 75 Number of Products by Stage and Target, H2 2015 77 Number of Products by Stage and Mechanism of Action, H2 2015 81 Number of Products by Stage and Route of Administration, H2 2015 84 Number of Products by Stage and Molecule Type, H2 2015 86 Atherosclerosis Therapeutics - Recent Pipeline Updates, H2 2015 211 Atherosclerosis - Dormant Projects, H2 2015 238 Atherosclerosis - Dormant Projects (Contd..1), H2 2015 239 Atherosclerosis - Dormant Projects (Contd..2), H2 2015 240 Atherosclerosis - Dormant Projects (Contd..3), H2 2015 241 Atherosclerosis - Dormant Projects (Contd..4), H2 2015 242 Atherosclerosis - Discontinued Products, H2 2015 243 Atherosclerosis - Discontinued Products (Contd..1), H2 2015 244
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
